CYPHERPUNK TECHNOLOGIES INC. Net Income (Loss) Available to Common Stockholders, Diluted
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Net Income (Loss) Available to Common Stockholders, Diluted of $39.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-12
- CYPHERPUNK TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $39.39M.
- CYPHERPUNK TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$77.17M.
- CYPHERPUNK TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $40.20M.
- CYPHERPUNK TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$3.30M.
- CYPHERPUNK TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was $4.82M.
- CYPHERPUNK TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$67.79M.
- CYPHERPUNK TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$81.41M.
- CYPHERPUNK TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$54.60M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.39M 10-Q · filed 2026-08-12 | -$37.78M 10-Q · filed 2026-08-12 | $2.43M derived: sum of 3 quarters · filed 2026-08-12 | -$877.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$77.17M 10-Q · filed 2026-05-14 | -$36.96M derived: sum of 2 quarters · filed 2026-05-14 | -$40.27M derived: sum of 3 quarters · filed 2026-05-14 | -$56.91M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $40.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $36.90M derived: sum of 2 quarters · filed 2026-03-16 | $20.26M derived: sum of 3 quarters · filed 2026-08-12 | $4.82M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$3.30M 10-Q · filed 2025-11-12 | -$19.95M derived: sum of 2 quarters · filed 2026-08-12 | -$35.38M 10-Q · filed 2025-11-12 | -$50.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$16.64M 10-Q · filed 2026-08-12 | -$32.08M 10-Q · filed 2026-08-12 | -$47.51M derived: sum of 3 quarters · filed 2026-08-12 | -$65.69M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$15.44M 10-Q · filed 2026-05-14 | -$30.87M derived: sum of 2 quarters · filed 2026-05-14 | -$49.04M derived: sum of 3 quarters · filed 2026-05-14 | -$69.40M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$15.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$33.61M derived: sum of 2 quarters · filed 2026-03-16 | -$53.97M derived: sum of 3 quarters · filed 2026-03-16 | -$67.79M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$18.18M 10-Q · filed 2025-11-12 | -$38.54M derived: sum of 2 quarters · filed 2025-11-12 | -$52.36M 10-Q · filed 2025-11-12 | -$64.82M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$20.36M 10-Q · filed 2025-08-14 | -$34.18M 10-Q · filed 2025-08-14 | -$46.65M derived: sum of 3 quarters · filed 2025-08-14 | -$60.34M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$13.82M 10-Q · filed 2025-05-13 | -$26.29M derived: sum of 2 quarters · filed 2025-05-13 | -$39.98M derived: sum of 3 quarters · filed 2025-05-13 | -$53.37M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$12.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$26.16M derived: sum of 2 quarters · filed 2025-03-26 | -$39.55M derived: sum of 3 quarters · filed 2025-03-26 | -$81.41M 10-K · filed 2025-03-26 |
| 2023-09-30 | -$13.70M 10-Q · filed 2024-11-13 | -$27.09M derived: sum of 2 quarters · filed 2024-11-13 | -$68.95M 10-Q · filed 2024-11-13 | -$81.05M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$13.39M 10-Q · filed 2024-08-12 | -$55.25M 10-Q · filed 2024-08-12 | -$67.36M derived: sum of 3 quarters · filed 2024-08-12 | -$82.45M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$41.86M 10-Q · filed 2024-05-13 | -$53.97M derived: sum of 2 quarters · filed 2024-05-13 | -$69.06M derived: sum of 3 quarters · filed 2024-05-13 | -$86.08M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$12.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$27.20M derived: sum of 2 quarters · filed 2024-03-18 | -$44.22M derived: sum of 3 quarters · filed 2024-03-18 | -$54.60M 10-K · filed 2024-03-18 |
| 2022-09-30 | -$15.09M 10-Q · filed 2023-11-13 | -$32.12M derived: sum of 2 quarters · filed 2023-11-13 | -$42.49M 10-Q · filed 2023-11-13 | -$53.28M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$17.02M 10-Q · filed 2023-08-14 | -$27.40M 10-Q · filed 2023-08-14 | -$38.19M derived: sum of 3 quarters · filed 2023-08-14 | -$49.33M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$10.38M 10-Q · filed 2023-05-15 | -$21.16M derived: sum of 2 quarters · filed 2023-05-15 | -$32.30M derived: sum of 3 quarters · filed 2023-05-15 | -$41.83M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$10.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$21.93M derived: sum of 2 quarters · filed 2023-03-24 | -$31.45M derived: sum of 3 quarters · filed 2023-03-24 | -$40.59M 10-K · filed 2023-03-24 |
| 2021-09-30 | -$11.14M 10-Q · filed 2022-11-14 | -$20.66M derived: sum of 2 quarters · filed 2022-11-14 | -$29.80M 10-Q · filed 2022-11-14 | -$36.51M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$9.53M 10-Q · filed 2022-08-12 | -$18.66M 10-Q · filed 2022-08-12 | -$25.37M derived: sum of 3 quarters · filed 2022-08-12 | -$32.43M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$9.13M 10-Q · filed 2022-05-13 | -$15.84M derived: sum of 2 quarters · filed 2022-05-13 | -$22.90M derived: sum of 3 quarters · filed 2022-05-13 | -$29.42M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$6.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$13.77M derived: sum of 2 quarters · filed 2022-03-11 | -$20.28M derived: sum of 3 quarters · filed 2022-03-11 | -$37.59M 10-K · filed 2022-03-11 |
| 2020-09-30 | -$7.06M 10-Q · filed 2021-11-12 | -$13.57M derived: sum of 2 quarters · filed 2021-11-12 | -$30.88M 10-Q · filed 2021-11-12 | -$38.87M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$6.52M 10-Q · filed 2021-08-13 | -$23.82M 10-Q · filed 2021-08-13 | -$31.82M derived: sum of 3 quarters · filed 2021-08-13 | -$39.75M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | -$17.30M 10-Q · filed 2021-05-14 | -$25.30M derived: sum of 2 quarters · filed 2021-05-14 | -$33.24M derived: sum of 3 quarters · filed 2021-05-14 | -$41.60M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | -$8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$15.93M derived: sum of 2 quarters · filed 2021-03-12 | -$24.30M derived: sum of 3 quarters · filed 2021-03-12 | -$33.26M 10-K · filed 2021-03-12 |
| 2019-09-30 | -$7.93M 10-Q · filed 2020-11-12 | -$16.30M derived: sum of 2 quarters · filed 2020-11-12 | -$25.26M 10-Q · filed 2020-11-12 | -$31.07M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | -$8.37M 10-Q · filed 2020-08-13 | -$17.33M 10-Q · filed 2020-08-13 | -$23.13M derived: sum of 3 quarters · filed 2020-08-13 | -$31.56M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | -$8.96M 10-Q · filed 2020-05-14 | -$14.77M derived: sum of 2 quarters · filed 2020-05-14 | -$23.19M derived: sum of 3 quarters · filed 2020-05-14 | |
| 2018-12-31 | -$5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$14.23M derived: sum of 2 quarters · filed 2020-03-16 | -$30.42M 10-K · filed 2020-03-16 | |
| 2018-09-30 | -$8.43M 10-Q · filed 2019-11-14 | -$24.62M 10-Q · filed 2019-11-14 | ||
| 2017-12-31 | -$7.07M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | -$13.88M derived: sum of 2 quarters · filed 2019-04-01 | -$30.44M 10-K · filed 2019-04-01 | |
| 2017-09-30 | -$6.82M 10-Q · filed 2018-11-09 | -$23.38M 10-Q · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |